These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 1684308

  • 1. Duration of neuroleptic treatment and relapse rate: a 5-year follow-up study with haloperidol decanoate.
    Youssef HA.
    Clin Neuropharmacol; 1991; 14 Suppl 2():S16-21; discussion S22-3. PubMed ID: 1684308
    [Abstract] [Full Text] [Related]

  • 2. Minimal effective dose and relapse--double-blind trial: haloperidol decanoate vs. placebo.
    Eklund K, Forsman A.
    Clin Neuropharmacol; 1991; 14 Suppl 2():S7-12; discussion S12-5. PubMed ID: 1684310
    [Abstract] [Full Text] [Related]

  • 3. [Long-term therapy of chronic schizophrenic patients with haloperidol decanoate].
    Roncoroni D.
    Psychiatr Prax; 1984 Mar; 11(2):56-8. PubMed ID: 6144121
    [Abstract] [Full Text] [Related]

  • 4. A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia.
    Chouinard G, Annable L, Campbell W.
    J Clin Psychopharmacol; 1989 Aug; 9(4):247-53. PubMed ID: 2570086
    [Abstract] [Full Text] [Related]

  • 5. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK, Hubbard JW, Marder SR, Marshall BD, Van Putten T.
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [Abstract] [Full Text] [Related]

  • 6. Haloperidol decanoate as a replacement for maintenance therapy with intramuscular fluphenazine decanoate in schizophrenia and other chronic psychoses.
    Roose K.
    Acta Psychiatr Belg; 1982 Jul; 82(2):216-23. PubMed ID: 7180558
    [Abstract] [Full Text] [Related]

  • 7. A practical loading dose method for converting schizophrenic patients from oral to depot haloperidol therapy.
    Wei FC, Jann MW, Lin HN, Piao-Chien C, Chang WH.
    J Clin Psychiatry; 1996 Jul; 57(7):298-302. PubMed ID: 8666571
    [Abstract] [Full Text] [Related]

  • 8. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R, Oosthuizen P, Koen L, Niehaus DJ, Medori R, Rabinowitz J.
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [Abstract] [Full Text] [Related]

  • 9. [Bromperidol decanoate in the residual phase of schizophrenia].
    Smeraldi E, Cocconcelli C, Canova L, Faravelli C, Marchetti FP, Mariani G, Rapisarda V.
    Minerva Psichiatr; 1996 Mar; 37(1):39-44. PubMed ID: 8926856
    [Abstract] [Full Text] [Related]

  • 10. Pharmacological long-term treatment strategies in first episode schizophrenia--study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia.
    Gaebel W, Möller HJ, Buchkremer G, Ohmann C, Riesbeck M, Wölwer W, Von Wilmsdorff M, Bottlender R, Klingberg S.
    Eur Arch Psychiatry Clin Neurosci; 2004 Apr; 254(2):129-40. PubMed ID: 15146342
    [Abstract] [Full Text] [Related]

  • 11. Clozapine maintenance therapy in schizophrenia.
    Gaszner P, Makkos Z.
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 May; 28(3):465-9. PubMed ID: 15093952
    [Abstract] [Full Text] [Related]

  • 12. [Evaluation of clinical usefulness of decaldol (haloperidol decanoate) produced by WZF Polfa in Warsaw in long-term treatment of schizophrenia].
    Morasiewicz J, Baranowski P, Borys J, Jańska-Skomorowska M, Kiejna A.
    Psychiatr Pol; 1995 May; 29(3):405-20. PubMed ID: 7652093
    [Abstract] [Full Text] [Related]

  • 13. Long-term maintenance therapy with quetiapine versus haloperidol decanoate in patients with schizophrenia or schizoaffective disorder.
    Glick ID, Marder SR.
    J Clin Psychiatry; 2005 May; 66(5):638-41. PubMed ID: 15889952
    [Abstract] [Full Text] [Related]

  • 14. Dosage strategies with long-acting injectable neuroleptics, including haloperidol decanoate.
    Kane JM.
    J Clin Psychopharmacol; 1986 Feb; 6(1 Suppl):20S-23S. PubMed ID: 2870088
    [Abstract] [Full Text] [Related]

  • 15. Haloperidol decanoate in schizophreniform disorders. Clinical and neuroendocrine aspects.
    Meco G, Casacchia M, Attenni M, Iafrate A, Castellana F, Ecari U.
    Acta Psychiatr Belg; 1983 Feb; 83(1):57-68. PubMed ID: 6613612
    [Abstract] [Full Text] [Related]

  • 16. Reducing the dose of depot neuroleptics in stable schizophrenia.
    Dale R, Longdon M, Seeman MV.
    J Psychiatry Neurosci; 1994 Jul; 19(4):278-81. PubMed ID: 7918349
    [Abstract] [Full Text] [Related]

  • 17. Continuation electroconvulsive therapy for relapse prevention in middle-aged and elderly patients with intractable catatonic schizophrenia.
    Suzuki K, Awata S, Takano T, Ebina Y, Iwasaki H, Matsuoka H.
    Psychiatry Clin Neurosci; 2005 Aug; 59(4):481-9. PubMed ID: 16048455
    [Abstract] [Full Text] [Related]

  • 18. [Modification of long-term schizophrenia by somato-therapeutic measures].
    Gross G, Huber G, Schüttler R.
    Psychiatr Clin (Basel); 1980 Aug; 13(3-4):179-92. PubMed ID: 6113621
    [Abstract] [Full Text] [Related]

  • 19. The effect of age on the pharmacological management of ambulatory patients treated with depot neuroleptic medications for schizophrenia and related psychotic disorders.
    Mamo DC, Sweet RA, Chengappa KN, Reddy RR, Jeste DV.
    Int J Geriatr Psychiatry; 2002 Nov; 17(11):1012-7. PubMed ID: 12404650
    [Abstract] [Full Text] [Related]

  • 20. [Intraindividual comparison of haloperidol decanoate and oxyprothepine in maintenance therapy in schizophrenic psychoses].
    Cesková E, Svestka J, Rysánek R.
    Cesk Psychiatr; 1993 Jan; 89(1):11-4. PubMed ID: 8099534
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.